President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

bluebird could fare better with its new cell-based gene therapy for SCD, Lyfgenia (lovotibeglogene autotemcel), which was cleared by the FDA in December and has a list price of $3.1 million.

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic... The Company will present at the Annual J.P. Morgan Healthcare Conference ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other chronic conditions.

Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania ...

After hours: January 30 at 5:30:00 PM EST ...